natgillin/translations-raw huggingface dataset:
Viekirax, give one fifth of the total daily dose of ciclosporin once daily with Viekirax.
Viekirax dajte eno petino celotnega dnevnega odmerka ciklosporina enkrat na dan z zdravilom Viekirax.
Viewing Window
Nadzorno okence
Viewing window
Okence
Viewing Window
Opazovalno okence
Viewing window
pregledno okence
Vifor Fresenius Medical Care Renal Pharma France 100-101 Terrasse Boieldieu
Vifor Fresenius Medical CareRenal Pharma France 100­101 Terrasse Boieldieu
Vigabatrin/efavirenz
vigabatrin/efavirenz gabapentin/efavirenz
Vigabatrin/Efavirenz Gabapentin/Efavirenz
varfarin/efavirenz acenokumarol/efavirenz
Vigilance for skin lesions is warranted and a medical evaluation of the skin is recommended at initiation, after at least one year and then at least yearly taking into consideration clinical judgement.
Bolnike velja pozorno spremljati glede morebitnega razvoja kožnih sprememb, pregled kože pa je priporočen na začetku zdravljenja in po najmanj enem letu zdravljenja, nato pa najmanj enkrat na leto po klinični presoji.
Vigilance for the timely detection of serious infection is recommended for patients receiving biological treatments for moderate to severe RA as signs and symptoms of acute inflammation may be lessened, associated with suppression of the acute phase reactants.
Med zdravljenjem zmernega do hudega revmatoidnega artritisa z biološkimi zdravili je treba nameniti pozornost pravočasnemu odkrivanju resnih okužb, kajti znaki in simptomi akutnega vnetja se zaradi zavrtja reaktantov akutne faze lahko zmanjšajo.
Vigorous shaking should be avoided.
Izogibati se je treba močnemu tresenju.
Vigorously swirl the vial without touching the rubber top with your fingers until the content is completely mixed.
Vialo močno vrtite, da vso vsebino povsem premešate, ob tem pa se s prsti ne dotikajte gumijastega pokrova.
VIII deficiency) who have developed inhibitors to factor VIII" and "treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency)". (see section 4.2 for information on paediatric use).
VIII) pri »indukciji imunske tolerance (ITI) pri bolnikih s hemofilijo A (dednim pomanjkanjem faktorja VIII), pri katerih so se pojavili zaviralci faktorja VIII,« in »zdravljenju in preventivi krvavitve pri bolnikih s hemofilijo A (dednim pomanjkanjem faktorja VIII)« (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
ViiV Healthcare UK Limited 980 Great West Road Brentford
ViiV Healthcare UK Limited 980 Great West Road BrentfordMiddlesex
ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Velika
ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.
ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Velika Britanija
Vilanterol (n=409)
vilanterol (n = 409)
Vilanterol 22 mcg (N = 421)
22 mcg vilanterola (N = 421)
Vilanterol is a long-acting beta-2 adrenergic agonist.
Vilanterol je dolgodelujoč agonist adrenergičnih receptorjev beta2.
Vilanterol is a long-acting beta-2 agonist.
Vilanterol je dolgodelujoči agonist beta-2 adrenergičnih receptorjev.
Vilanterol trifenatate is a selective long-acting, beta2-adrenergic agonist (LABA).
Vilanterolijev trifenatat je selektiven, dolgodelujoč agonist adrenergičnih receptorjev beta2 (LABA – long- acting, beta2-adrenergic agonist).
Vildagliptin 50 mg daily + glimepiride (N=132)
vildagliptin 50 mg dnevno + glimepirid (N=132)
Vildagliptin 50 mg twice daily +
vildagliptin 50 mg dvakrat
Vildagliptin 50 mg twice daily + metformin (N=143)
vildagliptin 50 mg dvakrat dnevno + metformin (N=143)
Vildagliptin 50 mg twice daily + metformin + glimepiride (N=152)
vildagliptin 50 mg dvakrat dnevno + metformin + glimepirid (N=152)
Vildagliptin 50 mg twice daily + pioglitazone (N=136)
vildagliptin 50 mg dvakrat dnevno + pioglitazon (N=136)
Vildagliptin is indicated in the treatment of type 2 diabetes mellitus in adults: As monotherapy
Vildagliptin je indiciran za zdravljenje sladkorne bolezni tipa 2 pri odraslih: kot monoterapija:
Vildagliptin, which is a dipeptidyl peptidase 4 (DPP-4) inhibitor, works by blocking the breakdown of ‘incretin’ hormones in the body.
Vildagliptin, ki je zaviralec dipeptidil peptidaze 4 (DPP-4), deluje tako, da zavira razgradnjo hormonov inkretinov v telesu.
Vildagliptin/metformin 50 mg/1000 mg twice daily reduced HbA1c by -1.82% ,vildagliptin/metformin 50 mg/500 mg twice daily by -1.61%, metformin 1000 mg twice daily by -1.36% and vildagliptin 50 mg twice daily by -1.09% from a mean baseline HbA1c of 8.6%.
Odmerek kombinacije vildagliptin/metformin 50 mg/1000 mg dvakrat na dan je znižal vrednost HbA1c za 1,82 %, odmerek kombinacije vildagliptin/metformin 50 mg/500 mg dvakrat na dan za 1,61 %, metformin 1000 mg dvakrat na dan za 1,36 % in vildagliptin 50 mg dvakrat na dan za 1,09 % od povprečne izhodiščne vrednosti HbA1c 8,6 %.
vildagliptin/metformin hydrochloride
vildagliptin/metforminijev klorid
Village Moraiya; Taluka Sanand, Ahmedabad – 382213 Gujarat India
Village Moraiya; Taluka: Sanand, Ahmedabad – 382213 Gujarat, Indija
Vimizim 1 mg/ml concentrate for solution for infusion
Vimizim 1 mg/ml koncentrat za raztopino za infundiranje
Vimizim contains sodium and sorbitol
Zdravilo Vimizim vsebuje natrij in sorbitol.
Vimizim has to be diluted with sodium chloride 9 mg/ml (0.9 %) solution for infusion using aseptic technique.
Zdravilo Vimizim je treba po aseptičnem postopku razredčiti z raztopino natrijevega klorida 9 mg/ml (0,9 %) za infundiranje.
Vimizim is supplied as a concentrate for solution for infusion.
Zdravilo Vimizim je na voljo v obliki koncentrata za raztopino za infundiranje.
Vimizim may be started at as young as an age possible and is intended for long term use.
Zdravilo Vimizim se lahko uvede pri čim mlajših bolnikih in je namenjeno za dolgoročno uporabo.
Vimizim treatment should be supervised by a physician experienced in the management of patients with MPS IVA or other inherited metabolic diseases.
Zdravljenje z zdravilom Vimizim mora nadzorovati zdravnik z izkušnjami pri zdravljenju bolnikov s sindromom MPS IVA ali drugimi dednimi boleznimi presnove.
Vimpat 10 mg/ml (only for the outer carton)
Vimpat 10 mg/ml (samo za zunanjo ovojnino).
Vimpat 10 mg/ml solution for infusion
Vimpat 10 mg/ml raztopina za infundiranje
Vimpat 10 mg/ml solution for infusion is a clear, colourless solution.
Zdravilo Vimpat 10 mg/ml raztopina za infundiranje je bistra, brezbarvna raztopina.
Vimpat 10 mg/ml solution for infusion Lacosamide
Vimpat 10 mg/ml raztopina za infundiranje lakozamid
Vimpat 10 mg/ml syrup is a slightly viscous clear, colourless to yellow-brown liquid.
Zdravilo Vimpat 10 mg/ml sirup je rahlo viskozna, bistra tekočina brezbarvne do rumeno-rjave barve.
Vimpat 100 mg are dark yellow, oval film-coated tablets with a debossed ‘SP’ on one side and ‘100’ on the other side.
Zdravilo Vimpat 100 mg so temno rumene, ovalne filmsko obložene tablete z vtisnjeno oznako ‘SP’ na eni strani in oznako ‘100’ na drugi.
Vimpat 100 mg film-coated tablets Lacosamide
Vimpat 100 mg filmsko obložene tablete lakozamid
Vimpat 150 mg are salmon, oval film-coated tablets with a debossed ‘SP’ on one side and ‘150’ on the other side.
Zdravilo Vimpat 150 mg so lososove barve ovalne filmsko obložene tablete z vtisnjeno oznako ‘SP’ na eni strani in oznako ‘150’ na drugi.
Vimpat 150 mg are salmon, oval film-coated tablets with a debossed ‘SP’ on one side and ‘150’ on the other side.
Zdravilo Vimpat 150 mg so lososove barve, ovalne filmsko obložene tablete z vtisnjeno oznako ‘SP’ na eni strani in oznako ‘150’ na drugi.
Vimpat 150 mg film-coated tablets Lacosamide
Vimpat 150 mg filmsko obložene tablete lakozamid
Vimpat 200 mg are blue, oval film-coated tablets with a debossed ‘SP’ on one side and ‘200’ on the other side.
Zdravilo Vimpat 200 mg so modre, ovalne filmsko obložene tablete z vtisnjeno oznako ‘SP’ na eni strani in oznako ‘200’ na drugi.
Vimpat 200 mg film-coated tablets Lacosamide
Vimpat 200 mg filmsko obložene tablete lakozamid
Vimpat 50 mg are pinkish, oval film-coated tablets with a debossed ‘SP’ on one side and ‘50’ on the other side.
Zdravilo Vimpat 50 mg so rožnate, ovalne filmsko obložene tablete z vtisnjeno oznako ‘SP’ na eni strani in oznako ‘50’ na drugi.
Vimpat 50 mg film-coated tablets Lacosamide
Vimpat 50 mg filmsko obložene tablete lakozamid
Vimpat has been given to you by your doctor to reduce the number of fits.
Zdravilo Vimpat vam bo dal zdravnik za zmanjšanje števila napadov.
Vimpat infusion can be used to initiate treatment.
Infuzija zdravila Vimpat se lahko uporablja kot uvod v zdravljenje.
Vimpat is a medicine containing the active substance lacosamide.
Vimpat je zdravilo, ki vsebuje zdravilno učinkovino lakozamid.
Vimpat is available in bottles of 200 ml and 465 ml.
Zdravilo Vimpat je na voljo v steklenicah po 200 ml in 465 ml.
Vimpat is available in packs of 14, 56 and 56 x 1 film-coated tablets and in multipacks comprising 3 cartons, each containing 56 tablets.
Zdravilo Vimpat je na voljo v pakiranjih po 14, 56 in 56 x 1 filmsko obložena tableta in v večkratnem pakiranju, ki vsebuje 3 škatle s po 56 tabletami.
Vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy.
Zdravilo Vimpat je indicirano za dopolnilno zdravljenje parcialnih napadov s sekundarno generalizacijo ali brez nje pri odraslih in mladostnikih (starih 16-18 let) z epilepsijo.
Vimpat is not recommended for children and adolescents aged under 16 years.
Zdravilo Vimpat pri otrocih in mladostnikih, mlajših od 16 let, ni priporočeno.
Vimpat is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation).
Zdravilo Vimpat se uporablja samo pri obliki epilepsije, pri kateri napad v začetku prizadane le eno stran možganov, čeprav se kasneje lahko razširi na večje predele obeh strani možganov (parcialni napadi s sekundarno generalizacijo ali brez nje).
Vimpat is used in addition to other antiepileptic medicines.
Zdravilo Vimpat se uporablja skupaj z drugimi antiepileptiki.
Vimpat is used to treat partial-onset seizures (epileptic fits starting from one specific part of the brain) as an add-on to other antiepileptic medicines in patients with epilepsy aged 16 years and older.
Zdravilo Vimpat se uporablja za zdravljenje napadov parcialnega izvora (epileptičnih napadov, ki se sprožijo v določenem delu možganov) kot dodatno zdravljenje k drugim antiepileptičnim zdravilom pri bolnikih z epilepsijo, starih 16 let ali več.
Vimpat may cause dizziness, which could increase the risk of accidental injury or a fall.
Zdravilo Vimpat lahko povzroča omotico, kar lahko poveča tveganje za naključne poškodbe ali padce.
Vimpat must be administered twice a day, once in the morning and once in the evening, at about the same time each day.
Zdravilo Vimpat morate prejeti dvakrat na dan, enkrat zjutraj in enkrat zvečer, vsak dan ob približno enakem času.
Vimpat must be taken twice a day, once in the morning and once in the evening, at about the same time each day.
Zdravilo Vimpat morate vzeti dvakrat na dan, enkrat zjutraj in enkrat zvečer, vsak dan ob približno enakem času.
Vimpat must not be used in people who are hypersensitive (allergic) to lacosamide or any of the other ingredients, or who have second or third degree AV block (a type of heart rhythm disorder).
Zdravila Vimpat ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) na lakozamid ali na katero koli drugo sestavino zdravila ali ki imajo AV blok druge ali tretje stopnje (vrsto motnje srčnega ritma).
Vimpat solution for infusion can be administered intravenously without further dilution or can be diluted with sodium chloride 9 mg/ml (0.9%) solution for injection, glucose 50 mg/ml (5%) solution for injection or lactated Ringer’s solution for injection.
Raztopino za infundiranje Vimpat lahko intravensko apliciramo brez dodatnega redčenja ali jo lahko redčimo z raztopino natrijevega klorida 9 mg/ml (0,9 %) za injiciranje, raztopino glukoze 50 mg/ml (5 %) za injiciranje ali raztopino Ringerjevega laktata za injiciranje
Vimpat solution for infusion can be administered without further dilution, or may be diluted with the following solutions: sodium chloride 9 mg/ml (0.9%), glucose 50 mg/ml (5%) or lactated Ringer’s solution.
Zdravilo boste lahko prejeli brez predhodnega redčenja ali pa bo zdravilo prej razredčeno z eno od naslednjih raztopin: raztopina natrijevega klorida 9 mg/ml (0,9 %), raztopina glukoze 50 mg/ml (5 %) ali raztopina Ringerjevega laktata.
Vimpat solution for infusion was found to be physically compatible and chemically stable when mixed with the following diluents for at least 24 hours and stored in glass or PVC bags at temperatures up to 25°C.
Zdravilo Vimpat raztopina za infundiranje je fizikalno kompatibilna in kemijsko stabilna vsaj 24 ur pri temperaturi do 25°C, če je shranjena v steklenicah ali PVC vrečah in je bila pripravljena s spodaj navedenimi raztopinami.
Vimpat syrup contains sodium methyl parahydroxybenzoate (E219), which may cause allergic reactions (possibly delayed). ).
Zdravilo Vimpat sirup vsebuje natrijev metilparahidroksibenzoat (E219), ki lahko povzroča alergijske reakcije (možno z zakasnitvijo).
Vimpat syrup contains: sorbitol (a type of sugar).
Zdravilo Vimpat sirup vsebuje: sorbitol (vrsta sladkorja).
Vimpat tablets and oral syrup are bioequivalent.
Tablete in peroralni sirup zdravila Vimpat so bioekvivalentni.
Vimpat taken by mouth has been compared with placebo (a dummy treatment) in three main studies involving a total of 1,308 patients.
Učinkovitost peroralne uporabe zdravila Vimpat so primerjali z učinkovitostjo placeba (zdravila brez zdravilne učinkovine) v treh glavnih študijah, v katerih je sodelovalo 1 308 bolnikov.
Vimpat therapy can be initiated with either oral or i.v. administration.
Zdravljenje z zdravilom Vimpat lahko začnemo s peroralnim ali intravenskim dajanjem.
Vimpat treatment initiation pack contains 4 different packages (one for each tablet strength) with 14 tablets each, for the first 2 to 4 weeks of therapy depending on the patient´s response and tolerability.
Paket zdravila Vimpat za začetek zdravljenja vsebuje 4 različna pakiranja (eno za vsako jakost tablet), vsako s po 14 tabletami, ki glede na bolnikov odziv in prenašanje zdravila zadostuje za prva 2 do 4 tedne zdravljenja.
Vimpat with alcohol
Zdravilo Vimpat skupaj z alkoholom
Vimpat, at doses of 200 or 400 mg a day, was more effective than placebo in reducing the number of seizures.
Zdravilo Vimpat v odmerkih 200 ali 400 mg na dan je bilo učinkovitejše od placeba pri zmanjševanju števila napadov.
Vinblastine
vinblastin
Vinca alkaloids
Alkaloidi vinke
Vinca alkaloids (vincristine, vinblastine) (P-gp substrates)
Vinka alkaloidi (vinkristin, vinblastin) (substrati P-gp)
Vincamine i.v.
vinkamin i.v.
Vincristine
vinkristin
Vincristine (used to treat certain types of cancer) since the simultaneous use of vincristine and asparaginase may increase the risk of certain side effects.
Vinkristin (uporablja se za zdravljenje določenih vrst raka), ker lahko sočasna uporaba vinkristina in asparaginaze zveča tveganje za nekatere neželene učinke.
vincristine 1.3 mg/m2 i.v., days 1, 8, 15, 21; prednisolone 60 mg/m2/day oral
vinkristin 1,3 mg/m2 i.v., 1., 8., 15., 21. dan; prednizolon 60 mg/m2/dan peroralno
Vincristine 1.3 mg/m2 i.v., days 1, 8, 15, 21; Prednisolone 60 mg/m2/day oral
vinkristin 1,3 mg/m² i.v., 1., 8., 15., 21. dan; prednizolon 60 mg/m²/dan peroralno
Vincristine, vinblastine and other vinca alkaloids (used to treat cancer)
vinkristin, vinblastin in drugi vinka alkaloidi (ki jih uporabljamo za zdravljenje raka)
vincristine, vinblastine and other “vinca alkaloids” (used to treat cancer)
vinkristin, vinblastin in drugi alkaloidi vinke (uporabljajo se za zdravljenje raka),
vincristine, vinblastine, used for cancer, mycophenolate mofetil (MMF), used in transplant patients,
vinkristin, vinblastin, ki se uporabljata za zdravljenje raka, mofetilmikofenolat (MMF), ki se uporablja pri bolnikih po presaditvi,
Vinflunine initial dose of 250 mg/m²
Začetni odmerek vinflunina 250 mg/m²
Vinflunine initial dose of 320 mg/m²
Začetni odmerek vinflunina 320 mg/m²
Vinflunine is eliminated following a multi-exponential concentration decay, with a terminal half-life (t1/2) close to 40 h.
Vinflunin se eliminira z večeksponentnim koncentracijskim razpadom s terminalno razpolovno dobo (t1/2) približno 40 h.
Vinflunine is moderately bound to human plasma proteins (67.2±1.1%) with a ratio between plasma and whole blood concentrations of 0.800.12.
Vinflunin se zmerno veže na beljakovine človeške plazme (67,21,1 %) tako, da je razmerje med koncentracijo v plazmi in polni krvi 0,800,12.
Vinflunine pharmacokinetics was not modified in those patients, however based on hepatic biologic parameter modifications following vinflunine administration (gamma glutamyl transferases (GGT), transaminases, bilirubin), the dose recommendations are as follows:
Farmakokinetika vinflunina se pri teh bolnikih ne spremeni, na spremembah jetrnih bioloških parametrov (gama-glutamil-transferaze (GGT), transaminaze, bilirubin) po dajanju vinflunina, pa temeljijo naslednja priporočila:
Vinflunine treatment should be initiated under the responsibility of a physician qualified in the use of anticancer chemotherapy and is confined to units specialised in the administration of cytotoxic chemotherapy.
Zdravljenje z vinfluninom se mora začeti po nadzorom zdravnika, ki je usposobljen za uporabo kemoterapevtikov proti raku in je omejeno na zdravstvene enote, specializirane za dajanje citotoksičnih kemoterapij.
Violent shaking (seizures) and loss of consciousness;
ilovito tresenje (epileptični napad) in izguba zavesti,
Violent, uncontrollable muscular contractions often accompanied by unconsciousness that can be due to an epileptic attack (seizures).
Silovito in nenadzorovano krčenje mišic, ki ga pogosto spremlja nezavest in je lahko posledica epileptičnega napada (krči).
Vipdomet
Zdravilo Vipdomet
Vipdomet 12.5 mg/1000 mg film-coated tablets
Vipdomet 12,5 mg/1.000 mg filmsko obložene tablete
Vipdomet 12.5 mg/1000 mg film-coated tablets alogliptin/metformin hydrochloride
Vipdomet 12,5 mg/1000 mg filmsko obložene tablete alogliptin/metforminijev klorid
Vipdomet 12.5 mg/1000 mg tablets alogliptin/metformin hydrochloride
Vipdomet 12,5 mg/1000 mg tablete alogliptin/metforminijev klorid
Vipdomet 12.5 mg/850 mg film-coated tablets
Vipdomet 12,5 mg/850 mg filmsko obložene tablete
Vipdomet 12.5 mg/850 mg film-coated tablets alogliptin/metformin hydrochloride
Vipdomet 12,5 mg/850 mg filmsko obložene tablete alogliptin/metforminijev klorid
Vipdomet 12.5 mg/850 mg film-coated tablets Vipdomet 12.5 mg/1000 mg film-coated tablets Alogliptin/Metformin hydrochloride
Vipdomet 12,5 mg/850 mg filmsko obložene tablete Vipdomet 12,5 mg/1.000 mg filmsko obložene tablete alogliptin/metforminijev klorid
Vipdomet 12.5 mg/850 mg tablets alogliptin/metformin hydrochloride
Vipdomet 12,5 mg/850 mg tablete alogliptin/metforminijev klorid
Vipdomet combines two antihyperglycaemic medications with complementary and distinct mechanisms of action to improve glycaemic control in patients with type 2 diabetes mellitus: alogliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor, and metformin, a member of the biguanide class.
Zdravilo Vipdomet je kombinacija dveh antihiperglikemičnih zdravil s komplementarnim in ločenim mehanizmom delovanja, namenjeno za izboljšanje urejenosti glikemije pri bolnikih s sladkorno boleznijo tipa 2: alogliptina, zaviralca dipeptidil-peptidaze-4 (DPP-4) in metformina, ki spada v skupino bigvanidov.
Vipdomet contains two different medicines called alogliptin and metformin in one tablet:
Zdravilo Vipdomet v eni tableti združuje dve različni zdravilni učinkovini, imenovani alogliptin in metformin:
Vipdomet has no or negligible influence on the ability to drive and use machines.
Zdravilo Vipdomet nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Vipdomet is not known to affect your ability to drive and use machines.
Ni znano, če zdravilo Vipdomet vpliva na sposobnost za vožnjo in upravljanje s stroji.
Vipdomet is not recommended for use in patients with moderate and severe renal impairment and end-stage renal disease (creatinine clearance < 60 mL/min)(see section 4.3).
Pri bolnikih z zmerno ali hudo okvaro ledvic in bolnikih s končno ledvično odpovedjo (kreatininski očistek < 60 ml/min), uporaba zdravila Vipdomet ni priporočljiva (glejte poglavje 4.3).
Vipdomet should be taken twice daily because of the pharmacokinetics of its metformin component.
Zdravilo Vipdomet je treba zaradi farmakokinetike metformina jemati dvakrat na dan.
Vipdomet should not be used in patients with hepatic impairment (see section 4.2).
Pri bolnikih z okvaro jeter se zdravila Vipdomet ne sme uporabljati (glejte poglavje 4.2).
Vipdomet should not be used in patients with hepatic impairment (see sections 4.3 and 5.2).
Pri bolnikih z okvaro jeter se zdravila Vipdomet ne sme uporabljati (glejte poglavji 4.3 in 5.2).
Vipidia 12.5 mg film-coated tablets alogliptin
Vipidia 12,5 mg filmsko obložene tablete alogliptin
Vipidia 25 mg film-coated tablets alogliptin
Vipidia 25 mg filmsko obložene tablete alogliptin
Vipidia 25 mg film-coated tablets Vipidia 12.5 mg film-coated tablets Vipidia 6.25 mg film-coated tablets Alogliptin
Vipidia 25 mg filmsko obložene tablete Vipidia 12,5 mg filmsko obložene tablete Vipidia 6,25 mg filmsko obložene tablete alogliptin
Vipidia 6.25 mg film-coated tablets alogliptin
Vipidia 6,25 mg filmsko obložene tablete alogliptin
Vipidia contains the active substance alogliptin which belongs to a group of medicines called “oral anti-diabetics”.
Zdravilna učinkovina zdravila Vipidia je alogliptin, ki spada v skupino zdravil, imenovano “peroralni antidiabetiki”.
Vipidia has no or negligible influence on the ability to drive and use machines.
Zdravilo Vipidia nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Vipidia is not known to affect your ability to drive and use machines.
Ni znano, če zdravilo Vipidia vpliva na sposobnost za vožnjo in upravljanje s stroji.
Vipidia must not be used in patients who are hypersensitive (allergic) to the active substances or any of the ingredients or who have had serious allergic reactions to any DPP 4 inhibitor.
Zdravila Vipidia ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) zdravilne učinkovine ali katero koli drugo sestavino zdravila ali pri katerih se je kdaj v preteklosti pojavila huda alergijska reakcija na zaviralec DPP–4.
Vipidia should not be used during pregnancy or breast-feeding unless your doctor thinks it is clearly necessary.
Zdravila Vipidia med nosečnostjo ali dojenjem ne smete uporabljati, razen če zdravnik meni, da je uporaba nujno potrebna.
vir
tonavir
vir/ritona
↓ombitasvir
VIRACEPT 250 mg film-coated tablets
VIRACEPT 250 mg filmsko obložene tablete nelfinavir
Viracept 250 mg film-coated tablets Nelfinavir
Viracept 250 mg filmsko obložene tablete nelfinavir
VIRACEPT 250 mg film-coated tablets.
VIRACEPT 250 mg filmsko obložene tablete
VIRACEPT 250 mg film-coated tablets: Roche Pharma AG
VIRACEPT 250 mg filmsko obložene tablete: Roche Pharma AG
VIRACEPT 50 mg/g oral powder
VIRACEPT 50 mg/g peroralni prašek nelfinavir
Viracept 50 mg/g oral powder is a white to off-white powder.
Peroralni prašek Viracept 50 mg/g je bele do sivo bele barve.
Viracept 50 mg/g oral powder Nelfinavir
Viracept 50 mg/g peroralni prašek nelfinavir
VIRACEPT 50 mg/g oral powder.
VIRACEPT 50 mg/g peroralni prašek
Viracept BID (%)
Viracept dvakrat na dan (%)
Viracept can stop oral contraceptives (the pill) from working, so you should use other contraception methods (such as condoms) while you are taking Viracept.
Zdravilo Viracept lahko ustavi delovanje kontracepcijskih tablet, zato med jemanjem zdravila Viracept uporabljajte druge metode kontracepcije (kondomi).